drugset / Trial / NCT02387307
A Study of rSIFN-co in Subjects With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, phase I study of rSIFN-co (3 times a week via subcutaneous injection for 21 days, with 1 week of washout per cycle).
Timeline
- Start
- 2013-07
- Primary completion
- 2018-06
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon Alfacon-1 | Protein / enzyme biologic | 21 ug | Subcutaneous |
| Subject | Interferon Alfacon-1 | Protein / enzyme biologic | 24 ug | Subcutaneous |
| Subject | Interferon Alfacon-1 | Protein / enzyme biologic | 27 ug | Subcutaneous |
| Subject | Interferon Alfacon-1 | Protein / enzyme biologic | 30 ug | Subcutaneous |